Skip to main content
SpringerLink
Log in

Topische Therapie beim oberflächlichen Harnblasenkarzinom

  • Zum Thema: Urothelkarzinom der Harnblase
  • Published:
Der Urologe B

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Bahnson R, Brasman S, Greenberg R, Brown T, Dalkin B, Middleton R, Soloway MS, Steinberg G, Wajsman Z (1998) Multicenter efficiacy and safety study of intravesical AD 32 (Valrubicin) in the treatment of patients with refractory bladder carcinoma in situ. J Urol 159: 551 (A)

    Article  Google Scholar 

  2. Baniel J, Graus D, Engelstein D, Livne PM, Sella A (1998) Intravesical BCG treatment for primary T1 GIII TCC of the bladder. Eur Urol 33: 405 (A)

    Article  Google Scholar 

  3. Böhle A, Jocham D (1998) Die intravesikale Immuntherapie mit Bacillus Calmette Guérin-Fakten, Vergleich, Ergebnisse. Fischer, Stuttgart Jena Lübeck

  4. Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Boeken Kruger C, De Pauw M, Sylvester R (1995) Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of cancer randomized trials with Mitomycin C and Doxorubicin comparing early versus delayed instillations and short term versus longtermtratment. J Urol 153: 934–941

    Article  CAS  PubMed  Google Scholar 

  5. Bonfil RD, Russo DM, Schmilovich AJ, Garcia-Palazzo IB (1997) Intravesical therapy of vinorelbin tartrate: antitumor activity in orthotopic murine cell carcinoma of the bladder. J Urol 158: 912–915

    Article  CAS  PubMed  Google Scholar 

  6. Heike C, Wirth M (1999) An opinion poll of German urologists concerning the current treatment of pT1, GIII transitional cell carcinoma of the bladder. Eur Urol 35: 91 (A)

    Google Scholar 

  7. Herr MW (1997) Tumor progression and survival in patients with pT1, GIII bladder tumours: 15 year outcome. Br J Urol 80: 762–765

    Article  CAS  PubMed  Google Scholar 

  8. Lamm DL, Blumenstein B, Sarosdy M, Grossmann B, Crawford D (1997) Significant long-term patient benefit with BCG maintenance therapy: a southwest oncology group study. J Urology 157: 831 (A)

    Article  Google Scholar 

  9. Malmström P-U, Wijkström H, Lundholm C, Wester K, Cusch C, Norlen BJ (1999) 5-year followup of a randomized prospective study comparing Mitomycin C and Bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J Urol 161: 1124–1127

    Article  PubMed  Google Scholar 

  10. Martinez-Pinero JA, Flores N, Isorna S (1999) Comparison between a standard BCG does (81 mg) versus a three fold reduced dose (27 mg) in superficial bladder cancer. Final analysis of CUETO 90 008 prostpective study. Eur Urol 35: 153 (A)

    Google Scholar 

  11. Morales A, Chin JL (1997) Mycobacterial cell wall (MCW) as an alternative to BCG in the treatment of Carcinoma in situ (CIS) of the bladder: an efficiacy study. J Urol 157: 834 (A)

    Article  Google Scholar 

  12. Ofer N, Halachmi S, Madjar M, Issaq E, Moskovitz B, Dalai E,Aronson M (1999) The antineoplastic activity of gemcitabine on experimental superficial bladder cancer. Eur Urol 35: 99 (A)

    Google Scholar 

  13. Den Otter W, Dobrowolski Z, Bugajski A, Papla B, van der Mejden APM, Koten JW, Boon TA, Siedlar M, Zembela M (1998) Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesions in 8 of 10 patients. J Urol 159: 1183–1186

    Article  Google Scholar 

  14. Pansadoro V, Emiliozzi P, Defidio L, Donadio D, Florio A, Maurelli S, Lauretti S, Sternberg CN (1995) Bacillus Calmette-Guérin in the treatment of pT1, G III transitional cell carcinoma of the bladder: long term results. J Urol 154: 2054–2058 (A)

    Article  CAS  PubMed  Google Scholar 

  15. Rübben H, Otto T (1997) Harnblasenkarzinom. In: Rübben H (Hrsg) Uroonkologie. Springer, Berlin Heidelberg New York, S 85–167

    Chapter  Google Scholar 

  16. Vegt PD, van der Mejden AP, Sylvester R, Brausi M, Holtl W, de Balincourt C (1997) Does isoniazid reduce side effects of intravesical bacillus Calmette-Guérin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30 911. J Urol 157: 1246–1249

    Article  CAS  PubMed  Google Scholar 

  17. Vincenzo S, Ercole G, Vaccarella Pavone C, Pavone MM (1999) Adjuvant intravesical combination of Epirubicin and Mitomycin in T1 GIII transitional cell carcinoma of the bladder. Eur Urol 35: 94

    Google Scholar 

  18. Witjes JA, v. d. Mejden APM, Colette L, Sylvester R, Debruyne FMJ, v. Aubel A, Witjes WPM (1998) Long term follow-up of an EORTC randomized prospective trial comparing intravesical Bacille Calmette Guèrin-RIVM and Mitomycin C in superficial bladder cancer. Urology 52: 403–410

    Article  CAS  PubMed  Google Scholar 

  19. Witjes WPJ, Hall RR, Schulman CC, Zurlo M, Fittipaldo A, Riggi M, Debruyne F (1999) Bropirimin vs. BCG in BCG naive patients with carcinoma in situ of the urinary bladder. Results of a european randomized phase III trial. Eur Urol 33: 407 (A)

    Google Scholar 

  20. Zlotta AR, Drowart A, Van Vooren L-P, Simon J, Schulman CC, Huygen K (1998) What is the optimal schedule for intravesical BCG therapy: are six instillations necessary? Eur Urol 33: 402 (A)

Download references

Author information

Authors and Affiliations

  1. Urologische Universitätsklinik, Universitätskrankenhaus Eppendorf, Martinistraße 52, D-20 246, Hamburg

    M. G. Friedrich, S. Conrad & H. Huland

Authors
  1. M. G. Friedrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Conrad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Huland
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Friedrich, M.G., Conrad, S. & Huland, H. Topische Therapie beim oberflächlichen Harnblasenkarzinom. Der Urologe B 39, 307–309 (1999). https://doi.org/10.1007/s001310050307

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s001310050307

Search

Navigation